bioAffinity Technologies
BIAF
9 hedge funds and large institutions have $140K invested in bioAffinity Technologies in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
29% more funds holding
Funds holding: 7 → 9 (+2)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
21% less capital invested
Capital invested by funds: $177K → $140K (-$37.3K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.52K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$51 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$355 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$51 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $50.8K | – | – | – |
|
|
2
Two Sigma Investments
New York
| $25.2K | -$355 | -7 | -1% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $23.3K | +$33.9K | +667 | New |
|
4
State Street
Boston,
Massachusetts
| $21.5K | – | – | – |
|
5
Creative Planning
Overland Park,
Kansas
| $14.1K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4.71K | +$4.52K | +89 | +193% |
|
|
7
UBS Group
Zurich,
Switzerland
| $76 | -$51 | -1 | -33% |
|
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| $46 | +$51 | +1 | New |
|
9
Wells Fargo
San Francisco,
California
| $44 | – | – | – |
|
10
JP Morgan Chase
New York
| $9 | – | – | – |
|
BIAF Hedge Fund Activity: Q3 2023 in Review
9 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q3 2023, worth a combined $140K — down 21% from $177K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIAF positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $33.9K. The largest seller was Two Sigma Investments, cutting an estimated $355.
- 9 institutional investors held bioAffinity Technologies (BIAF) as of Q3 2023, up from 7 in Q2 2023.
- Funds reported $140K of bioAffinity Technologies stock for Q3 2023, down 21% quarter-over-quarter.
- 2 funds opened new bioAffinity Technologies positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest bioAffinity Technologies buyer in Q3 2023 was Vanguard Group, an estimated $33.9K added.
- The largest bioAffinity Technologies seller in Q3 2023 was Two Sigma Investments, an estimated $355 sold.
Based on aggregated 13F filings for Q3 2023.